Skip to main content

Table 5 Vitamin D dosage and all-cause mortality risk

From: Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies

Investigator

# patients

Follow up (months)

Dosage (ug/week)

Mean dosage (ug/week)

Hazard ratio

95% CI

Calcitrol

Naves-Diaz et al.

1304

54

<1.75

1.05

0.46

0.37–0.53

Naves-Diaz et al.

1053

54

1.75-3.5

2.38

0.58

0.49–0.70

Naves-Diaz et al.

432

54

3.5-7.0

4.69

0.64

0.50–0.83

Naves-Diaz et al.

184

54

>7.0

11.83

0.83

0.58–1.19

Paricalcitol

Kalantar-Zadeh et al.

5288

24

1.0-5.0

NA

0.53

0.50–0.57

Kalantar-Zadeh et al.

11965

24

5.0-10.0

NA

0.54

0.51–0.57

Kalantar-Zadeh et al.

8326

24

10.0-15.0

NA

0.54

0.51–0.57

Kalantar-Zadeh et al.

11816

24

>15.0

NA

0.73

0.69–0.77

Shinaberger et al.

9575

30

1.7-20.1

10.9

0.93

0.89–0.97

Shinaberger et al.

8277

30

4.6-25.8

15.2

0.88

0.84–0.94

Shinaberger et al.

5875

30

6.4-30.8

18.6

0.88

0.84–0.93